Document Detail

Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis.
MedLine Citation:
PMID:  12379615     Owner:  NLM     Status:  MEDLINE    
Oral administration of the novel anti-inflammatory peptide RDP58 markedly reduced the severity of dextran sulphate sodium (DSS) colitis as determined by clinical and quantitative histological criteria. The architecture of the colonic epithelium in DSS treated mice receiving RDP58 remained relatively normal compared with that of control DSS treated animals. 5-Bromo-2'-deoxyuridine (BrdU) labelling studies showed a pronounced inhibition of colonic epithelial cell proliferation during DSS treatment, which was partially reversed by RDP58 therapy. Remarkably, RDP58 almost completely prevented colonic epithelial cell death induced by DSS treatment. RDP58 therapy also inhibited the accumulation of neutrophils in the colon of DSS treated mice and effectively down regulated tumour necrosis factor (TNF) expression. Preservation of the intestinal mucosa by RDP58 may thus derive from its influence on TNF expression as well as additional anti-inflammatory properties. These findings indicate that RDP58 represents a new, orally available agent potentially useful in the treatment of inflammatory bowel disease.
R Boismenu; Y Chen; K Chou; A El-Sheikh; R Buelow
Related Documents :
25246915 - The correlation between follicular fluid pregnancy-associated plasma protein a levels, ...
7740005 - Mid-trimester fetal sex determination from maternal peripheral blood by fluorescence in...
2088735 - Transplacental transport of lead.
25450205 - Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy.
16773965 - Abruptio placentae and its complications at ayub teaching hospital abbottabad.
22344465 - Cervical remodeling in term and preterm birth: insights from an animal model.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  61 Suppl 2     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2002 Nov 
Date Detail:
Created Date:  2002-10-15     Completed Date:  2002-12-12     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  ii19-24     Citation Subset:  IM    
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Administration, Oral
Anti-Inflammatory Agents / therapeutic use*
Apoptosis / drug effects
Cell Division / drug effects
Colitis / chemically induced,  pathology,  prevention & control*
Dextran Sulfate
Epithelial Cells / drug effects,  pathology
Intestinal Mucosa / drug effects,  pathology
Mice, Inbred C57BL
Neutrophil Infiltration / drug effects
Peptides / therapeutic use*
Tumor Necrosis Factor-alpha / biosynthesis
Grant Support
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Peptides; 0/Tumor Necrosis Factor-alpha; 151232-75-6/allotrap; 9042-14-2/Dextran Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?
Next Document:  Role of RANKL and RANK in bone loss and arthritis.